Tumor Microenvironment– tag –
-
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
Dual-Target CAR T Therapy for Glioblastoma Drives Broad Immune Activation, NK Cell Response Correlates with Long-Term Survival in Penn Medicine Study
Vertex AI Search USA Overview Researchers at the Perelman School of Medicine and Abramson Cancer Center discovered that direct intra-cerebrospinal fluid (CSF) delivery of a dual-target CAR T-cell therapy induces a broad immune response i... -
China’s NMPA Grants World’s First Approval for Solid Tumor CAR T-Cell Therapy Satri-cel Targeting CLDN18.2 Positive Gastric Cancer
OncLive USA Overview OncLive's June 2026 GI oncology regulatory roundup highlights China's NMPA approval of CARsgen Therapeutics' satricabtagene autoleucel (satri-cel), the first solid tumor CAR T-cell therapy for Claudin18.2-positive ad... -
CAR-NK Cell Therapy for Solid Tumors: Promising Safety and Off-the-Shelf Potential Outpace CAR-T
Cell Reports Medicine (via PubMed) USA Overview A new review highlights chimeric antigen receptor (CAR)-modified natural killer (NK) cells as a promising immunotherapy strategy for solid tumor treatment. Compared to CAR-T cell therapy, C... -
China Grants World’s First Solid Tumor CAR-T Approval for Satri-cel in Advanced Gastric Adenocarcinoma
Fierce Biotech USA Overview China's National Medical Products Administration (NMPA) has approved CARsgen Therapeutics' solid tumor CAR-T cell therapy, satri-cel, for HER2-negative, Claudin18.2-positive advanced gastric and gastroesophage... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a... -
Allogeneic CAR-T Cell Therapies Promise to Overcome Autologous Challenges and Expand Therapeutic Potential in Solid Tumors
PubMed (Review Article) Global Overview This review article details how allogeneic CAR-T cell therapies demonstrate clinical benefits in B-cell malignancies and offer the potential to overcome key limitations of autologous CAR-T, such as...
12